Atrial Fibrillation
Friday, May 17th, 2013
J Am Coll Cardiology: May 21, 2013 Objectives This study sought to determine the risk of ischemic stroke (IS)/thromboembolism (TE) associated with renal impairment and its incremental predictive value over established risk stratification scores (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke, […]
Atrial Fibrillation
Friday, May 17th, 2013
Future Medicine: May 13, 2013 Aim: To assess, through a systematic review, evidence for the effects of antiarrhythmic drugs (AADs) on cardiovascular (CV) hospitalization and mortality.Materials & methods: English language articles were identified using MEDLINE, EMBASE and the Cochrane Clinical Trial Registry and were screened for study applicability and methodological quality. Results: Out of 3526 identified studies, 38 were […]
Atrial Fibrillation
Friday, May 17th, 2013
J Am Coll Cardiology: May 1, 2013 Objective s: To evaluate the results associated with left atrial appendage closure (LAAC) with the Amplatzer Cardiac Plug (ACP) in patients with non-valvular atrial fibrillation (NVAF) and absolute contraindication for anticoagulation therapy. Background Little data exist on the late outcomes following LAAC in patients with absolute contraindication for warfarin. Read […]
Atrial Fibrillation
Saturday, May 11th, 2013
JACC: May 1, 2013 Objective The aim of this study was to examine the effect of continuous positive airway pressure (CPAP) therapy on atrial fibrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (PVI). Background OSA is a predictor of AF recurrence following PVI. However the impact of CPAP therapy on PVI […]
Atrial Fibrillation
Saturday, May 11th, 2013
JMCP: May 1, 2013 BACKGROUND: Atrial fibrillation (AF) imposes a substantial clinical and
economic burden on the U.S. health care system. Despite national guidelines that recommend oral anticoagulation for stroke prevention, the literature consistently reports its underuse in AF patients with moderate to high stroke risk. OBJECTIVE: To assess the economic burden of underuse and […]
Atrial Fibrillation
Saturday, May 11th, 2013
EP Lab Digest: April 30, 2013 Atrial fibrillation can be a scary ailment. Out of nowhere, the heart can race, causing fatigue, dizziness, and a profound sense of loss of control. Afib patients don’t feel in charge of their own bodies. Then, doctors give them instructions with little or no explanation, making their scary condition […]
Atrial Fibrillation
Thursday, May 2nd, 2013
Europace: May 5, 2013 New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs […]
Atrial Fibrillation
Thursday, May 2nd, 2013
Ann Pharmacother April 19, 2013 OBJECTIVE: To summarize the available evidence on the issues in health economics related to oral anticoagulation for stroke prevention in atrial fibrillation (AF) in the US. DATA SOURCES: A literature review was performed using PubMed, EMBASE, Cochrane Library, and International Pharmaceutical Abstracts, as well as the websites of professional organizations. STUDY SELECTION AND […]
Atrial Fibrillation
Thursday, May 2nd, 2013
Nature Reviews Cardiology: April 16, 2013 Atrial fibrillation (AF) is the most-common sustained arrhythmia observed in clinical practice, but response to therapy is highly variable between patients. Current drug therapies to suppress AF are incompletely and unpredictably effective and carry substantial risk of proarrhythmia and noncardiac toxicities. The limited success of therapy for AF is […]
Atrial Fibrillation
Thursday, May 2nd, 2013
J Am Heart Assoc: March 18, 2013 Background Tools for the prediction of atrial fibrillation (AF) may identify high‐risk individuals more likely to benefit from preventive interventions and serve as a benchmark to test novel putative risk factors. Methods and Results Individual‐level data from 3 large cohorts in the United States (Atherosclerosis Risk in Communities [ARIC] study, the […]
